Add to ORKGAbstract Background: We previously demonstrated in vitro that zidovudine (AZT) selects for A371V in the connection domain and Q509L in ribonuclease H (RNase H) domain of HIV-1 reverse transcriptase (RT) which, together with the thymidine analog mutations D67N, K70R and T215F, confer greater than 100-fold AZT resistance. The goal of the current study was to determine whether AZT monotherapy in HIV-1 infected patients also selects the A371V, Q509L or other mutations in the Cterminal domains of HIV-1 RT
BACKGROUND: The catalytically active 66-kDa subunit of the human immunodeficiency virus type 1 (HIV-...
Background. The connection domain mutation N348I confers resistance to zidovudine (AZT) and is assoc...
BACKGROUND: The connection domain mutation N348I confers resistance to zidovudine (AZT) and is assoc...
<div><h3>Background</h3><p>We previously demonstrated <em>in vitro</em> that zidovudine (AZT) select...
BACKGROUND: We previously demonstrated in vitro that zidovudine (AZT) selects for A371V in the conne...
BACKGROUND: We previously demonstrated in vitro that zidovudine (AZT) selects for A371V in the conne...
Background: We previously demonstrated in vitro that zidovudine (AZT) selects for A371V in the conne...
We previously demonstrated in vitro that zidovudine (AZT) selects for A371V in the connection domain...
that zidovudine (AZT) selects for A371V in the connection domain and Q509L in ribonuclease H (RNase...
that zidovudine (AZT) selects for A371V in the connection domain and Q509L in ribonuclease H (RNase...
Background: We previously demonstrated in vitro that zidovudine (AZT) selects for A371V in the conne...
Although anti-human immunodeficiency virus type 1 (HIV-1) therapies have become more sophisticated a...
Current antiretroviral therapy (ART) has reduced morbidity and mortality from HIV-1 infection, but t...
Current antiretroviral therapy (ART) has reduced morbidity and mortality from HIV-1 infection, but t...
Background. The connection domain mutation N348I confers resistance to zidovudine (AZT) and is assoc...
BACKGROUND: The catalytically active 66-kDa subunit of the human immunodeficiency virus type 1 (HIV-...
Background. The connection domain mutation N348I confers resistance to zidovudine (AZT) and is assoc...
BACKGROUND: The connection domain mutation N348I confers resistance to zidovudine (AZT) and is assoc...
<div><h3>Background</h3><p>We previously demonstrated <em>in vitro</em> that zidovudine (AZT) select...
BACKGROUND: We previously demonstrated in vitro that zidovudine (AZT) selects for A371V in the conne...
BACKGROUND: We previously demonstrated in vitro that zidovudine (AZT) selects for A371V in the conne...
Background: We previously demonstrated in vitro that zidovudine (AZT) selects for A371V in the conne...
We previously demonstrated in vitro that zidovudine (AZT) selects for A371V in the connection domain...
that zidovudine (AZT) selects for A371V in the connection domain and Q509L in ribonuclease H (RNase...
that zidovudine (AZT) selects for A371V in the connection domain and Q509L in ribonuclease H (RNase...
Background: We previously demonstrated in vitro that zidovudine (AZT) selects for A371V in the conne...
Although anti-human immunodeficiency virus type 1 (HIV-1) therapies have become more sophisticated a...
Current antiretroviral therapy (ART) has reduced morbidity and mortality from HIV-1 infection, but t...
Current antiretroviral therapy (ART) has reduced morbidity and mortality from HIV-1 infection, but t...
Background. The connection domain mutation N348I confers resistance to zidovudine (AZT) and is assoc...
BACKGROUND: The catalytically active 66-kDa subunit of the human immunodeficiency virus type 1 (HIV-...
Background. The connection domain mutation N348I confers resistance to zidovudine (AZT) and is assoc...
BACKGROUND: The connection domain mutation N348I confers resistance to zidovudine (AZT) and is assoc...